RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Homology Medicines Stock

Homology Medicines Net Income 2024

Homology Medicines Net Income

-66.1 M USD

Ticker

QTTB

ISIN

US4380831077

WKN

A2JGTY

In 2024, Homology Medicines's profit amounted to -66.1 M USD, a -41.49% increase from the -112.96 M USD profit recorded in the previous year.

The Homology Medicines Net Income history

YEARNET INCOME (undefined USD)
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

Homology Medicines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Homology Medicines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Homology Medicines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Homology Medicines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Homology Medicines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Homology Medicines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Homology Medicines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Homology Medicines’s growth potential.

Homology Medicines Revenue, EBIT and net profit per share

DateHomology Medicines RevenueHomology Medicines EBITHomology Medicines Net Income
2026e0 undefined-107.89 M undefined-66.98 M undefined
2025e0 undefined-71.4 M undefined-57.94 M undefined
2024e0 undefined-56.95 M undefined-66.1 M undefined
20231.16 M undefined-92.1 M undefined-112.96 M undefined
20223.21 M undefined-133.28 M undefined-5.01 M undefined
202133.97 M undefined-95.95 M undefined-95.76 M undefined
20202.7 M undefined-130.26 M undefined-128.69 M undefined
20191.67 M undefined-109.94 M undefined-103.92 M undefined
20185.32 M undefined-59.93 M undefined-55.58 M undefined
20170 undefined-29.66 M undefined-29.99 M undefined
20160 undefined-10 M undefined-8.05 M undefined

Homology Medicines stock margins

The Homology Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Homology Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Homology Medicines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Homology Medicines's sales revenue. A higher gross margin percentage indicates that the Homology Medicines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Homology Medicines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Homology Medicines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Homology Medicines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Homology Medicines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Homology Medicines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Homology Medicines Margin History

Homology Medicines Gross marginHomology Medicines Profit marginHomology Medicines EBIT marginHomology Medicines Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %-7,967.3 %-9,771.71 %
20220 %-4,152.03 %-156.07 %
20210 %-282.46 %-281.9 %
20200 %-4,824.44 %-4,766.3 %
20190 %-6,583.23 %-6,222.75 %
20180 %-1,126.5 %-1,044.74 %
20170 %0 %0 %
20160 %0 %0 %

Homology Medicines Aktienanalyse

What does Homology Medicines do?

Homology Medicines Inc. is a US-based company focused on the development of gene therapy technologies. The company was founded in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines Inc. aims to develop and market innovative gene therapies for rare diseases and genetic disorders. The company's goal is to develop new therapies through gene editing that can specifically modify genes to treat or alleviate symptoms of diseases. Homology Medicines bases its methodology on the natural processes of viral transport, through which double-stranded DNA is anchored into the cell. This allows the DNA to be directly introduced into living tissue, where it has systemic effects. Homology's gene therapy technology is based on the recombination of adenoviral vectors. The business model of Homology Medicines is to develop and market innovative gene therapies for rare diseases and genetic disorders. The company focuses on close collaboration with clinics to make the new therapies quickly and efficiently available to patients. The company has a close partnership with the National Institute of Health (NIH) to utilize its technology for gene therapy of rare diseases and genetic disorders. Homology Medicines Inc. specializes in three different branches of gene therapy: 1. In vivo gene therapy: In this method, gene therapies are directly introduced into the patient's tissue. Homology Medicines is working on developing new efficient methods for virus transport of therapeutics into the central nervous system and cardiovascular tissue. These methods aim to minimize the occurrence of unwanted effects. 2. Ex vivo gene therapy: In ex vivo gene therapy, a patient's cells are taken, modified, and then reintroduced into the patient. This method is particularly relevant for immune system disorders and cancer treatments. Homology Medicines is working on new efficient methods for the transport of modifiers into cells. 3. Genome editing therapy: In this final branch, Homology Medicines is working on developing genome editors that are specifically designed for defective genes. The technology is intended for the treatment of genetic diseases and restoring the functionality of defective genes. Homology Medicines Inc. is known for its low costs in gene therapy development. By utilizing natural viral transport methods and closely analyzing defects in humans, the company is able to quickly and cost-effectively develop therapies for patients. The company has already initiated several successful developments in gene therapy and continues to seek new innovations and developments to better meet the needs of patients. Homology Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Homology Medicines's Profit Margins

The profit margins of Homology Medicines represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Homology Medicines's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Homology Medicines's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Homology Medicines's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Homology Medicines’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Homology Medicines stock

How much profit has Homology Medicines made this year?

Homology Medicines has made -66.1 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -41.49% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Homology Medicines publish its earnings?

Homology Medicines publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Homology Medicines?

The profits of Homology Medicines are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Homology Medicines?

You can learn more about the earnings of Homology Medicines by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Homology Medicines pay?

Over the past 12 months, Homology Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Homology Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Homology Medicines?

The current dividend yield of Homology Medicines is .

When does Homology Medicines pay dividends?

Homology Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Homology Medicines?

Homology Medicines paid dividends every year for the past 0 years.

What is the dividend of Homology Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Homology Medicines located?

Homology Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Homology Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Homology Medicines from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Homology Medicines pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Homology Medicines in the year 2023?

In the year 2023, Homology Medicines distributed 0 USD as dividends.

In which currency does Homology Medicines pay out the dividend?

The dividends of Homology Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Homology Medicines

Our stock analysis for Homology Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Homology Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.